Physician profile
Jack A Ross
NPI 1942380506
$737.31
in general payments reported to CMS, 2019-2025
12 companies · $206 in 2025
The $206 reported for 2025 was more than what 81% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.33 · 2021: $12.20 · 2022: $22.66 · 2023: $63.12 · 2024: $405 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652 · Education: $21.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.19 |
| Education | $21.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $197.62 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Eagle Pharmaceuticals, INC. | $152.69 | 2024 | |
| Celltrion USA INC. | $79.29 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $70.57 | 2024-2025 | Dupixent |
| Janssen Biotech, INC. | $69.90 | 2023-2025 | Tremfya, Stelara, Remicade |
| Qol Medical, LLC | $46.85 | 2022-2024 | Sucraid |
| Teleflex LLC | $25.45 | 2019-2021 | |
| Enterra Medical, INC. | $24.41 | 2025 | |
| Intercept Pharmaceuticals, INC. | $19.55 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.39 | 2024 | Zeposia |
| Genzyme Corporation | $16.51 | 2024 | |
| Shire North American Group INC | $15.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.